Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Markers of Neutrophil Activation in Patients With RA

Neutrophils undergo marked activation and cell death in rheumatoid arthritis (RA), with neutrophil biomarkers providing added clinical value in monitoring and prognosis of RA patients, a new study found. Markers of neutrophil activation (calprotectin) and cell death (NET) were analyzed in plasma from 3 cross-sectional RA cohorts and healthy individuals using ELISA. A longitudinal inception cohort (n=247), seen for follow-up a median of 8 years later was used for predictive analysis. Researchers found:

  • Markers of neutrophil activation and cell death were increased in patients with RA vs healthy controls.
  • Calprotectin levels correlated with CDAI and distinguished between patients in remission and active disease.
  • Levels of NETs were associated with heightened levels of cell-free citrulline and inflammation.

Citation:

Bach M, et al. A neutrophil activation biomarker panel in prognosis and monitoring of patients with rheumatoid arthritis. [Published online ahead of print July 28, 2019]. Arthritis Rheumatol. doi:10.1002/art.41062.